摘要
背景:在各种类型的癌症中经常发现12p12-13的杂合性缺失(LOH)。 LOH12CR1是位于12p12-13区域内的七个关键基因之一。由LOH12CR1编码的蛋白质参与溶酶体的功能,其它功能仍不清楚。 目的:本研究旨在探讨LOH12CR1在结直肠癌发生中的潜在作用。 方法:采用免疫组化染色法检测174例结直肠癌组织中LOH12CR1的蛋白水平。通过回顾性研究进一步研究了LOH12CR1表达与患者预后之间的相关性。通过在四种结肠直肠癌细胞系和一种正常细胞系中敲低或过表达LOH12CR1来检查肿瘤抑制能力。 结果:在结直肠癌组织中观察到LOH12CR1蛋白显着降低(P <0.001)。通过下调p16INK4a和p21WAF1 / CIP1,LOH12CR1的敲低促进了结肠直肠癌细胞增殖,集落形成和加速的G1 / S细胞周期转变,而LOH12CR1的异位表达显示出相反的效果。 LOH12CR1的蛋白水平与p16INK4a和p21WAF1 / CIP1的表达密切相关。最重要的是,LOH12CR1的蛋白水平与结直肠癌的临床预后呈负相关。 结论:目前的结果表明LOH12CR1可能作为肿瘤抑制因子发挥作用。因此,LOH12CR1的功能丧失可能是结直肠癌发展的潜在驱动因素。检测LOH12CR1可用作结直肠癌患者的诊断和治疗评估方法。
关键词: LOH12CR1,肿瘤抑制因子,结肠直肠癌,细胞周期,G1 / S停滞,p16,p21。
Current Molecular Medicine
Title:LOH12CR1 is a Novel Tumor Suppressor Inhibiting Tumor Growth Through Deregulation of G1/S Checkpoint in Human Colorectal Carcinoma
Volume: 18 Issue: 1
关键词: LOH12CR1,肿瘤抑制因子,结肠直肠癌,细胞周期,G1 / S停滞,p16,p21。
摘要: Background: Loss of heterozygosity (LOH) of 12p12-13 has been frequently found in various types of cancer. LOH12CR1 is one of the seven critical genes located within the 12p12-13 region. The protein encoded by LOH12CR1 is involved in the function of lysosomes and its other functions are still unclear.
Objective: The aim of this study is to investigate the potential roles of LOH12CR1 in the development of colorectal cancer.
Methods: A total of 174 colorectal cancer tissues were used to examine the protein level of LOH12CR1 by immunohistochemistry staining. The correlation between LOH12CR1 expression and the patient prognosis was further investigated through retrospective study. The tumor suppression capacity was examined by knockdown or overexpression of LOH12CR1 in four colorectal cancer cell lines and one normal cell line.
Results: Significant decrease of LOH12CR1 protein was observed in colorectal cancerous tissues (P<0.001). Knockdown of LOH12CR1 promoted colorectal cancer cell proliferation, colony formation, and accelerated G1/S cell cycle transition through downregulation of p16INK4a and p21WAF1/CIP1, while ectopic expression of LOH12CR1 displayed the opposite effects. The protein level of LOH12CR1 was well correlated with the expression of p16INK4a and p21WAF1/CIP1. Most importantly, the protein level of LOH12CR1 negatively correlated with clinical prognosis of colorectal carcinomas.
Conclusion: The present results suggest that LOH12CR1 might function as a tumor suppressor. Thus, loss of function of LOH12CR1 might be a potential driver in the development of colorectal carcinoma. Detection of LOH12CR1 could be used as a method for diagnosis and therapeutic assessment of patients with colorectal cancer.
Export Options
About this article
Cite this article as:
LOH12CR1 is a Novel Tumor Suppressor Inhibiting Tumor Growth Through Deregulation of G1/S Checkpoint in Human Colorectal Carcinoma, Current Molecular Medicine 2018; 18 (1) . https://dx.doi.org/10.2174/1566524018666180608084005
DOI https://dx.doi.org/10.2174/1566524018666180608084005 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry Angiogenesis as a therapeutic target in breast cancer
Mini-Reviews in Medicinal Chemistry Genetic Instability Influences Drug Response in Cancer Cells
Current Drug Targets Novel Prodrugs for the Treatment of Colonic Diseases Based on 5-Aminosalicylic Acid, 4'-eranyloxyferulic Acid, and Auraptene: Biological Activities and Analytical Assays
Current Drug Delivery Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer
Current Medicinal Chemistry miR-135a Suppresses Calcification in Senescent VSMCs by Regulating KLF4/STAT3 Pathway
Current Vascular Pharmacology Synergistic Effect of Epigenetic Inhibitors Decitabine and Suberoylanilide Hydroxamic Acid on Colorectal Cancer In vitro
Current Molecular Pharmacology Dual Function of Nitric Oxide in Carcinogenesis, Reappraisal
Current Drug Metabolism Functional Genomic Approaches Targeting the Wnt Signaling Network
Current Drug Targets Importance and Limitations of Chemotherapy Among the Available Treatments for Gastrointestinal Tumours
Anti-Cancer Agents in Medicinal Chemistry Computational Approaches for Predicting Causal Missense Mutations in Cancer Genome Projects
Current Bioinformatics A Review on the Expression and Metabolic Features of Orphan Human Cytochrome P450 2S1 (CYP2S1)
Current Drug Metabolism Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review
Current Cancer Drug Targets Critical microRNAs in Lung Cancer: Recent Advances and Potential Applications
Anti-Cancer Agents in Medicinal Chemistry Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs
Current Protein & Peptide Science Targeting the EGFR Pathway for Cancer Therapy
Current Medicinal Chemistry Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects
Current Pharmaceutical Biotechnology Recent Developments of Platinum-based Anticancer Drugs- Detection and Analysis in Biological Samples
Current Organic Chemistry Role of Renin-Angiotensin System in Vascular Endothelial Dysfunction of Pregnancy-Induced Hypertension
Current Hypertension Reviews